Publication
A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
Journal Paper/Review - Nov 4, 2009
du Bois A, Huober Jens, Stopfer P, Pfisterer J, Wimberger P, Loibl S, Reichardt V L, Harter P
Units
PubMed
Doi
Citation
du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S, Reichardt V, Harter P. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol 2009; 21:370-5.
Type
Journal Paper/Review (English)
Journal
Ann Oncol 2009; 21
Publication Date
Nov 4, 2009
Issn Electronic
1569-8041
Pages
370-5
Brief description/objective
The purpose of the phase I dose-escalation study was to evaluate the maximum tolerated dose (MTD) of BIBF 1120, an oral triple angiokinase inhibitor of vascular endothelial growth factor, platelet derived growth factor and fibroblast growth factor receptors, combined with paclitaxel and carboplatin.